| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer | Director | President &CEO
3 companies
Traber Peter G is a Chief Medical Officer at RNAC, with reported holdings spanning 3 companies. Recent filings cover 8 purchases and 10 sales. Those positions are worth an estimated $4.9M at current prices.
Our model assigns Traber Peter G a middling insider score of 59/100, based on 11 past trades. Over a 12-month horizon, 54.5% of those trades were profitable, with an average 12-month return of -4.3%.
Traber Peter G's largest disclosed position is in RNAC as Chief Medical Officer, worth about $4.0M. Net of sales, the recent Form 4 record there shows accumulation of 74,206 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 8, 2018 | GALT Galectin Therapeutics Inc | President &CEO | Sale+OE | 70,000 | $5.86 | $409,997.00 | -39.5% | |
| Aug 12, 2015 | GALT Galectin Therapeutics Inc | President &CEO | Buy | 2,000 | $2.00 | $4,000.00 | +1.9% | |
| Jun 1, 2015 | GALT Galectin Therapeutics Inc | President &CEO | Buy | 4,000 | $2.53 | $10,120.00 | +3.9% |